Drugs / YFV-17D
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial · 1 missed | ||||||
| Phase 1/2 | NCT00723489 | Aug 2008 → Apr 2011 | atopic eczema | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Missed primary |
| Phase 41 trial | ||||||
| Phase 4 | NCT01290055 | Apr 2019 → Oct 2024 | yellow fever | Sri Edupuganti | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YFV-17D | “The goal of this study is to use the live attenuated yellow fever vaccine, YFV-17D (YF-VAX®, Sanofi Pasteur) as a safe and effective model to study a primary, acute viral...” NCT01290055 ↗ |
| Known as | Live Yellow Fever Vaccine | “Live Yellow Fever Vaccine (YFV-17D)” NCT00723489 ↗ |
| Modality | Vaccine | “live attenuated yellow fever virus (YFV) vaccination” PMID 24331381 ↗ Dec 2013 |
| Route | Subcutaneous | “YFV-17D by subcutaneous administration” NCT00723489 ↗ |